2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1582

Clinical Correlations and Expression Pattern of the Autoimmunity Susceptibility Factor Diora-1 in Primary Sjögren’s Syndrome
Abstract Number: 524

Clinical Course of Interstitial Lung Disease in Rheumatoid Arthritis Patients in Clinical Practice
Abstract Number: 580

Clinical Effectiveness of Tofacitinib 11mg Once Daily (QD) Versus Tofacitinib 5mg Twice Daily (BID) in the Corrona US RA Registry
Abstract Number: L10

Clinical Efficacy of Leflunomide/Hydroxychloroquine Combination Therapy in Patients with Primary Sjogren’s Syndrome: Results of a Placebo-Controlled Double-Blind Randomized Clinical Trial
Abstract Number: 1207

Clinical Evaluation Correlates Poorly with Ultrasound and Magnetic Resonance Imaging of Joints and Entheses in Early Peripheral Spondyloarthritis
Abstract Number: 1807

Clinical Features and Disease Course of Neurologic Involvement in Behcet’s Disease
Abstract Number: 1884

Clinical Features and Outcome of Patients with Polyarteritis Nodosa – a Global Collaborative Study
Abstract Number: 2973

Clinical Features and Pulmonary Function Test Findings Associated with Large Airway Disease in Relapsing Polychondritis
Abstract Number: 1313

Clinical Features and Timing of Studies in Interstitial Lung Disease with Autoimmune Disease Features: Do Autoantibody Panels Improve Diagnostic Yields and/or Increase Costs?
Abstract Number: 2939

Clinical Features Associated with Severe Lower Bowel Involvement in Systemic Sclerosis
Abstract Number: 1645

Clinical Features of Axial Spondyloarthritis Patients Diagnosed in Secondary Versus a Tertiary Hospital
Abstract Number: 2659

Clinical Features, Damage Accrual and Survival in Patients with Familial Systemic Lupus Erythematosus (SLE): Data from a Multiethnic, Multinational Latin American Lupus Cohort
Abstract Number: 1448

Clinical Impact of Articular Ultrasound in Diagnosis and Follow-up of Patients with Polyarthritis
Abstract Number: 2861

Clinical Laboratory Telephone Communication Outreach to Rheumatology Patients Improves Guideline-Concordant Timeliness of Monitoring of Conventional and Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
Abstract Number: 2893

Clinical Outcomes and Response to Anti-Thrombotic Treatment Among Patients with Concomitant Lupus Nephritis and Thrombotic Microangiopathy: A Multicenter Cohort Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].